DolPHIN2 |

Mother-to-child transmission of HIV is preventable, and we have a duty to ensure the burden of HIV is not handed down across generations.

image source: pexels

The DolPHIN 2 programme investigates the safe and effective use of dolutegravir for women who present with untreated HIV in late pregnancy

The team at the Infectious Diseases Institute, Kampala

DolPHIN 2 is a multinational project led by the University of Liverpool which aims to reduce the rate of mother to child transmission (MTCT) of HIV through research into a new HIV drug called dolutegravir.

How we work

About DolPHIN 2

Read about the challenges that the DolPHIN 2 project seeks to address and why.

The DolPHIN 2 Consortium

Learn more about our multinational research consortium, comprising partners in Europe and sub-Saharan Africa.

Community Voices

Collaboration with the community is at the heart of DolPHIN 2. Click here to learn more about our community engagement, and to hear from some of our study participants.

Resources

10 Mar 2021

DolPHIN2 Infographic

The DolPHIN 2 Clinical Trial is designed to yield high-quality evidence on the efficacy and safety of dolutegravir in late presenting pregnant women, to allow definitive recommendations for use of dolutegravir to reduce MTCT in this high-risk scenario.

Video

03 Dec 2019

HIV on Trial

Meet our research team, hear from some of our research participants and learn more about the DolPHIN story so far.

Video

28 Nov 2019

They become strong when they see me doing this

Jackie Kyeyune, a peer mother living with HIV, discusses how she uses her lived experience to support and inspire the DolPHIN 2 trial participants.

Video

28 Nov 2019

Trial Management at the Ugandan site

Dr Kenneth Kintu, trial manager at the IDI site, discusses the challenges and rewards of the study, and his hopes for the future

Video

View all Resources

News

The Ugandan Team Celebrates World Breastfeeding Week

08 Aug 2019

DolPHIN-2 presents primary outcome analysis at CROI 2019

05 Mar 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

WHO released a statement on 18 May 2018 relating to a potential safety issue affecting women living with HIV using dolutegravir at the time of conception.

20 Jun 2018

View all News and Events

@UoLDolPHIN2 on Twitter

RT @CatrionaWaitt: @IDIMakerere @UoLDolphin2 @VirTUAL_UoL @MRC_Uganda @CHAINUganda @okoboi25 https://t.co/iqwyNuaf3B

1 month 2 days ago

RT @Academic_MedEdu: The #LiverpoolCourse is excited to invite clinical case submissions for this year’s workshop. Do you have an interesting/challenging case involving #DDIs or a #pharmacology problem with #ARVs? Submit here by 30 September 2021 >> https://t.co/GIWxuxmZxw #HIV @hivinteractions https://t.co/WX2HJ5rZCJ

1 month 1 week ago

RT @CatrionaWaitt: Looking forward to #WBW2021 with the theme that breastfeeding is a shared responsibility. @Makerere Nursing Association is hosting an important seminar to discuss a range of related issues. You are welcome to join via the link. #MUNSAbreastfeedingweek https://t.co/TO05BwRV2W

2 months 3 weeks ago

RT @HIViBase: Community perspectives on: ensuring informed choices & enrolment of women in clinical trials. Access full session: https://t.co/VrAgd7029c Editing: @msclairelawrie. @4Mproject @SalamanderTrust @MakingWavesNet @ShareEastLondon @ukcab @savoy__truffle @BakitaKK @susancolehaley https://t.co/uLfvccCRkB

2 months 3 weeks ago

RT @CatrionaWaitt: 'Lack of researchers trained in pharmacology with interest in the pregnant [and lactating...] woman." We are committed to change that perception! @ShakirAtoyebi @annazecharia @BritPharmSoc @wellcometrust @profchloeorkin @pregnancyethics @UoLDolphin2 @VirTUAL_UoL @IMPAACTNetwork https://t.co/sWUTQgcgNf

3 months 2 weeks ago

Join one of our DolPHIN2 investigators @CatrionaWaitt for this discussion starting shortly https://t.co/j8mNSG66vc

3 months 3 weeks ago

RT @UNITAID: Excluding pregnant women from clinical trials can leave them more vulnerable. To show that such trials are not only needed, but can also be done, @UNITAID funded a trial of a new #HIV treatment specifically in pregnant women. Learn more in @POLITICOEurope: https://t.co/IztKFbXXxF

4 months 4 days ago

Celebrating #InternationalClinicalTrialsDay Thank you to everyone who contributes to DolPHIN2 especially our participants #whywedoresearch #ICTD2021

5 months 2 days ago

Happy Nurses’ Day! Thank you to all our DolPHIN2 research nurses. Find out more about a typical day for a study nurse. #InternationalNursesDay https://t.co/XvQxSFR0QS

5 months 1 week ago

Celebrating #InternationalDayoftheMidwife and the midwives who delivered the DolPHIN2 infants Watch Sanyu's Story about Giving Birth on https://t.co/baFO7Zvjzr

5 months 2 weeks ago

RT @CatrionaWaitt: European HIV Clinical Forum 2021: a mix of plenaries from the experts, interactive Q&A and debate. Aimed at optimising HIV management in Europe, will also be of interest to global colleagues and registration is FREE FOR HEALTHCARE WORKERS. Don't miss out! https://t.co/UXKnPJLPNc https://t.co/AASvbTAREG

5 months 2 weeks ago

Co-investigator @CatrionaWaitt will be speaking at the @Academic_MedEdu #HIV clinical forum register at https://t.co/jfv9FCcDR0 https://t.co/LpkM6WNGin

5 months 2 weeks ago

The D2 Consortium

The DolPHIN 2 consortium is a multinational partnership comprising five research organisations and our funder, Unitaid.

DolPHIN2

Search

How we work

About DolPHIN 2

The DolPHIN 2 Consortium

Community Voices

Resources

DolPHIN2 Infographic

HIV on Trial

They become strong when they see me doing this

Trial Management at the Ugandan site

News

The Ugandan Team Celebrates World Breastfeeding Week

DolPHIN-2 presents primary outcome analysis at CROI 2019

DolPHIN-2 Study team's response to WHO's statement on the safety of dolutegravir in pregnancy

@UoLDolPHIN2 on Twitter

The D2 Consortium

University of Liverpool

Liverpool School of Tropical Medicine

Infectious Diseases Institute

University of Cape Town

Radboud University Medical Centre

Unitaid

Contact us

Follow us